Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Other financing activities (2017 - 2025)

Conmed's Other financing activities history spans 15 years, with the latest figure at $4000.0 for Q4 2025.

  • For Q4 2025, Other financing activities fell 98.68% year-over-year to $4000.0; the TTM value through Dec 2025 reached $170000.0, down 43.89%, while the annual FY2025 figure was $170000.0, 43.89% down from the prior year.
  • Other financing activities reached $4000.0 in Q4 2025 per CNMD's latest filing, down from $147000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $15.4 million in Q3 2022 to a low of -$5.0 million in Q3 2021.
  • Average Other financing activities over 5 years is $2.6 million, with a median of $574000.0 recorded in 2024.
  • Peak YoY movement for Other financing activities: soared 3494.6% in 2023, then plummeted 792.54% in 2025.
  • A 5-year view of Other financing activities shows it stood at $5.3 million in 2021, then skyrocketed by 192.71% to $15.4 million in 2022, then plummeted by 91.87% to $1.2 million in 2023, then plummeted by 75.76% to $303000.0 in 2024, then crashed by 98.68% to $4000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNMD's Other financing activities are $4000.0 (Q4 2025), $147000.0 (Q3 2025), and $483000.0 (Q2 2025).